Clinical trials: Intraocular Inflammation
- Condition Intraocular Inflammation
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Behcet Disease
1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement
Primary objective of the study was to evaluate the safety and efficacy of canakinumab on the clinical and inflammatory findings of Behced Disease patients with neurologic and vascular involvement.
- Trial name
- Behcet (NCT02756650)
- Testing
- Canakinumab
- Where
- Turkey (Türkiye)
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Uveitis; Posterior, Disorder
Study Assessing Double-masked Uveitis Treatment
The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.
- Trial name
- SAKURA (NCT01358266)
- Testing
- DE-109 44 ug, DE-109 440 ug, DE-109 880 ug
- Where
- 151 sites in United States, Argentina and 15 more
- Volunteers
- 592 people
- Sponsor
- Santen Inc.
Uveitis, Uveitis, Posterior
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- AZALEA (NCT03097315)
- Testing
- 4 mg CLS-TA Suprachoriodal Injection
- Where
- 10 sites in United States
- Volunteers
- 38 people
- Sponsor
- Clearside Biomedical, Inc.
Uveitis
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear…
- Trial name
- NCT04088409
- Testing
- Baricitinib, Adalimumab
- Where
- 20 sites in France, Germany and 3 more
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Endogenous Anterior Uveitis
Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis
The purpose of this study was to demonstrate that difluprednate 0.05% (Durezol) dosed 4 times daily is noninferior to prednisolone 1% (Pred Forte) dosed 8 times daily for the treatment of endogenous anterior uveitis.
- Trial name
- NCT01201798
- Testing
- Difluprednate 0.05% ophthalmic emulsion, Prednisolone acetate 1.0% ophthalmic suspension
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Alcon Research
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
This was a multi-center, randomized, active-controlled, open-label study. Approximately 24 patients with active, non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy were enrolled.
- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
- Trial name
- NCT01526889
- Testing
- LFG316, Conventional Therapy
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Uveitis, Uveitis, Posterior
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
A study to evaluate the safety and efficacy of a fluocinolone acetonide intravitreal (FAI) insert in the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Intermediate
- Trial name
- NCT05070728
- Testing
- FAI Insert
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Inflammation, Cataract
A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery
This is a prospective, real-world study aimed to evaluate the efficacy and safety of Dexycu in treating postoperative inflammation of cataracts.
- Trial name
- NCT06497699
- Testing
- Dexycu
- Where
- 2 sites in China
- Volunteers
- 263 people
- Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Noninfectious Uveitis
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
- Trial name
- NCT00685399
- Testing
- AIN457, AIN 457
- Where
- 23 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Non-Infectious Uveitis of the Posterior Segment of the Eye
A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program
The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA…
- Trial name
- SPRING (NCT02251938)
- Testing
- DE-109 440 μg
- Where
- 25 sites in United States, Austria and 4 more
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Non Infectious Uveitis
LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
This is a Phase III study to assess the efficacy and safety of DE-109 440 µg every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye (NIU-PS).
- Trial name
- NCT03711929
- Testing
- DE-109 Intravitreal Injections, DE-109 Intravitreal Injections (Open Label)
- Where
- 65 sites in United States, Argentina and 2 more
- Volunteers
- 145 people
- Sponsor
- Santen Inc.
Non-infectious Uveitis
A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis
In this study, PP-001 is assessed for safety and efficacy in patients diagnosed with non-infectious chronic uveitis. PP-001 is a novel small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase) and has shown…
- Trial name
- NCT03634475
- Testing
- PP-001
- Where
- 9 sites in Austria, Belgium and 3 more
- Volunteers
- 12 people
- Sponsor
- Panoptes Pharma GmbH
Macular Edema
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.
- Trial name
- NCT04976777
- Testing
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbbVie
Uveitis
38 Week Extension Study to CAIN457C2303
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with…
- Trial name
- SHIELD (NCT01093846)
- Testing
- AIN457
- Where
- 25 sites in United States, Egypt and 12 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Uveitis, Posterior, Uveitis, Intermediate
Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)
The main reason for this study is to see if Acthar Gel can reduce inflammation in the uvea. Also, safety information when using it for this purpose will be collected.
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- NCT03656692
- Testing
- Acthar Gel
- Where
- 8 sites in United States
- Volunteers
- 5 people
- Sponsor
- Mallinckrodt
Uveitis, Intermediate Uveitis
Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
- Trial name
- NCT01789320
- Testing
- triamcinolone acetonide (Triesence®)
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Clearside Biomedical, Inc.
Non-infectious Anterior Uveitis
A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
This is a randomized, multi-center, investigator masked, comparator controlled study. The purpose of this study is to determine the efficacy and safety of NS2 in patients with non-infectious acute anterior uveitis.
- Trial name
- NCT02406209
- Testing
- NS2, Prednisolone acetate ophthalmic suspension (1%)
- Where
- 15 sites in United States
- Volunteers
- 45 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Non-infectious Anterior Uveitis
A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis
The objective of this study is to evaluate the safety of TRS01 eye drops in participants with active non-infectious anterior uveitis .
- Trial name
- NCT04222712
- Testing
- TRS01 eye drops
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Tarsier Pharma
Uveitis
Efficacy and Safety of Adalimumab in Patients With Active Uveitis
A study comparing the safety and efficacy of adalimumab compared with placebo in patients with active uveitis.
- Trial name
- VISUAL l (NCT01138657)
- Testing
- Adalimumab, Prednisone
- Volunteers
- 239 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Non-infectious Anterior Uveitis, Uveitic Glaucoma
TRS4Vision - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
The primary objective of this study is to evaluate the efficacy and safety of TRS01 eye drops compared to active comparator in subjects with active non-infectious anterior uveitis with or without uveitic glaucoma
- Trial name
- NCT05042609
- Testing
- TRS01, FDA approved steroid eye drop (masked)
- Where
- 30 sites in United States, France and 1 more
- Volunteers
- 142 people
- Sponsor
- Tarsier Pharma